An urgent need for efficacious disease-modifying therapies is required to slow down Parkinson's disease (PD) progression. Iron is required as a cofactor in metabolic processes throughout the body and specifically in tissues of high oxygen consumption, such as the central nervous system. The redox chemistry of iron is critical for neurotransmitter regulation as well as mitochondrial oxidative phosphorylation, nitric oxide metabolism, and oxygen transport. 1 Iron homeostasis involves the orchestration of systemic and cellular networks for the acquisition, internal distribution, and utilization of iron. 2 Disruption of links can lead to abnormal redistribution of iron, causing deleterious consequences (siderosis) either by localized accumulation and/or deficits in specific cellular compartments or tissues. Excessive labile iron in the substantia nigra pars compacta (SNc) has become a pathognomonic hallmark of PD and leads to increased production of noxious reactive oxygen species (ROS), which is also prevalent in PD. Conversely, a deficiency in iron impairs energy production 2 and can also cause dopaminergic neurodegeneration in mice. 3 In mammalian models, chelators that scavenge intracellular iron protect against oxidative neuronal damage. However, these strong iron chelation regimens are designed to treat systemic siderosis and are not suitable for PD patients, as iatrogenic iron depletion and anemia may ensue. A moderate iron chelation modality that conserves systemic iron offers a novel therapeutic strategy for neuroprotection (Table 1) .
Iron in Dopaminergic Neurons
Iron is particularly abundant in SNc dopaminergic neurons as an integral component of tyrosine hydroxylase-dependent dopamine synthesis as well as other enzymatic and nonenzymatic reactions associated with dopamine metabolism. 4 The identification of substantial brain labile nonheme high-spin complexes, which increase with age, 5 might explain iron's catalytic role in the generation of noxious ROS by Fenton chemistry involving hydrogen peroxide. In part, this results from the oxidative deamination of dopamine Relevant conflicts of interests/financial disclosure: The authors have no financial disclosures to make or potential conflicts of interest to report in relation to this study. and reduced by iron chelation 29, 30 Pivotal interplay between iron, dopamine, and a-synuclein pathology to influence dopaminergic neurotransmission and disease progression?
-Therapeutic targets for neuroprotection and dopasensibility?
What is the therapeutic concept of "conservative" iron chelation -Neuroprotection in PD models by iron chelation [1] [2] [3] [7] [8] [9] [10] [11] 34, 35 -Dopaminergic neuronal death by iron deficiency 3 -Concept: low dose of deferiprone redeploys captured iron to extracellular apotransferrin, and subsequent distribution avoids iron deficit: preclinical efficacy and clinical safety 9, 36, 37 Efficacy to be confirmed with large trial in progress? (FAIRPARK-II) -Trials also in progress for PKAN-2, ALS, AD Careful therapeutic iron redistribution by conservative chelation based on iron scavenging and redeployment ( Fig. 3 ) may afford neuroprotection without anemia (risk of reversible neutropenia in 1%-3%) (Continued)
by monoamine oxidase and the formation of metastable iron-dopamine complexes, which in turn lead to dopamine auto-oxidation and quinone formation. The sequestration of various potentially toxic products sequestered by neuromelanin confers a distinctive pigmentation on the SNc. However, as the neuromelanin sanctuary for toxins is lost during PD, 4 the labile endogenous autooxidation products of dopamine can strongly impair respiration by the mitochondrial complexes I and IV. A high-energy demand because of autonomous pacemaking activity might also render the SNc more susceptible to imbalances in labile iron levels and the ensuing ROS production. 6 
Iron Deposits Measured in the SNc in PD
Iron accumulation has been identified in the SNc of postmortem brains of patients as well as in all parkinsonian animal models. 1, 2, [7] [8] [9] [10] [11] This has been confirmed in patients by iron-sensitive high-field MRI (3 and 7 Tesla) with a quantitative weighted T2* sequence showing a higher R2* value (Fig. 1, Table 1 ). 9, 12, 13 Longitudinal studies and a meta-analysis have identified progressive iron accumulation in the SNc through the course of disease. [12] [13] [14] Visual assessment of dorsolateral SN hyperintensity by susceptibility weighted imaging can differentiate PD versus controls, 15 and these observations have been corroborated by reduced transverse relaxation, 16 another measurement of rate sequence. More recently, a novel MRI approach with quantitative susceptibility mapping (QSM) has demonstrated superior sensitivity for mapping changes in nonheme iron levels, 17, 18 and a new sequence of magnetization transfer contrast has identified a local neuromelanin density reduction in the SNc. 19 Transcranial ultrasound that visualizes hyperechogenicity of SNc tissue has also identified increased iron levels relating to alterations in iron metabolism genes. 20, 21 What Could Be the Cellular Mechanisms Implicated in Iron Accumulation?
Impaired Iron Release
Ferroportin is depleted in parkinsonian models including intoxication with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA).
1 Depletion of either amyloid precursor protein (APP) or tau function causes neuronal iron retention as well as iron-dependent nigral cell loss, and both proteins are decreased in the SNc in PD. 7, 22 Cellular iron egress by ferroportin may also be assisted by ceruloplasmin, and mice deficient of this enzyme develop deferiprone (DFP) rescuable age-dependent iron elevation and parkinsonism. 7 In PD patients low ceruloplasmin activity has been identified in the SN, cerebrospinal fluid, and serum. 1 Point mutations in the ceruloplasmin gene also associate with parkinsonism 11 and SN hyperechogenicity in PD. 7, 23 The table does not contain the exhaustive list of references on each topic. Reviews are frequently quoted because of space and reference limitations. PD, Parkinson's disease; SNc, substantia nigra pars compacta; SNr, substantia nigra pars reticulate; VTA, ventral tegmental area; MRI, magnetic resonance imaging; SWI, susceptibility-weighted imaging; ROS, reactive oxygen species; 6-OHDA, 6-hydroxydopamine; ALS, amyotrophic lateral sclerosis; PKAN-2, pantothenate kinase-associated neurodegeneration type 2; AD, Alzheimer's disease.
Altered Iron Storage
The limited capacity of neurons to sequester surplus iron into ferritin molecules 1,2 is complemented by expressing neuromelanin as an alternative "iron sink." 4 However, such capacities might be exceeded in PD, 2 potentially leading to increased ferritin immunoreactivity in microglia in the SN. 24 Elevated levels of iron-loaded ferritin over time may contribute to agerelated neurodegeneration by acting as a metastable reservoir for iron.
1,2,4

Increased Iron Uptake
Single-nucleotide polymorphisms in transferrin (Tf) and its receptor (TfR) identified from PD case-control studies may have a protective role via changes to Tfbound iron transport into the cell. 25 Lactoferrin and its receptor may also play a similar role. 26 Finally, iron accumulation in the SNc of patients and MPTP mice correlates with elevation of the iron importer divalent metal transporter 1.
27
Is There Interplay Between Iron and aSynuclein?
Iron markedly induces aggregation of a-synuclein into intracellular inclusions (ie, Lewy bodies). 28 Consistent with iron deposition, QSM measurements follow a pattern with the distributions of a-synuclein in PD pathology. 17 Since the identification that iron can translationally increase protein levels of a-synuclein through its promoter region, 28 more recent evidence has suggested a role for a-synuclein in modulating iron homeostasis. Depletion of a-synuclein in a functional location impairs the capacity for TfR to import iron and indicates that a-synuclein could modulate clatherinmediated endocytosis. 28 Neonatal iron feeding of a transgenic mouse model overexpressing human asynuclein bearing the A53T mutation exacerbates both PD-related motor and nonmotor phenotypes. 29 Accordingly, iron chelation reduces the amount of insoluble asynuclein aggregates 29 and rescues behavioral deficits 30 in murine models of genetic PD.
Ferroptosis -A New Iron-Dependent Cell Death Pathway in PD That May Yield Further Therapeutic Options
A new iron-dependent cell death pathway that has recently come to light has strong implications in PD neuropathology. Ferroptosis appears to be selectively triggered by an iron-dependent mechanism with key features including lipid peroxidation, specific depletion of glutathione peroxidases-4 to alter glutathione protection, mitochondriopathy, and distinct morphological modifications that are independent from other cell death pathways (eg, apoptosis, necrosis, and autophagy). 31, 32 Inhibition of the xCT cystine/glutamate antiporter during ferroptosis consequentially prevents cystine uptake into the cell and leads to lower levels of glutathione synthesis and increases cellular availability of labile iron to catalyze lipid peroxidation (Fig. 2) . 31 Ferroptosis is associated with the pathogenic changes observed in PD, as well as with the classical in vitro and in vivo pro-oxidant models. 33 This includes nigral iron elevation, mitochondriopathy, glutathione depletion, lipid peroxidation, elevated ROS generation, and oxidation of dopamine. 33 Ferroptosis can be rescued by iron chelation (eg, with DFP), 31, 33 supporting the requirement for iron in the initiation of this cell death pathway. Importantly, a range of inhibitors with greater specificity to ferroptosis (eg, liproxstatin-1) have recently been designed with promising future implications in disease modification.
FIG. 1.
Iron overload in the substantia nigra. Postmortem mesencephalon analysis reveals that the dopaminergic neurons, naturally stained in black by auto-oxidation of dopamine in control (upper left), have disappeared in PD (upper right). Perls staining with pink color enhancement shows that the SN is normally rich in iron (second line, left) but is iron-overloaded in PD (second line, right). Brain magnetic resonance imaging of the mesencephalon. The quantitative weighted T2* sequence shows a higher intensity (R2* 5 1/T2*) in PD (bottom right) than in control (bottom left). The quantitative susceptibility mapping (3 Tesla) distinguishes the iron in the normal SN (third line, left), but the same nuclei in the iron-overloaded PD case exhibits hyperintensity (third line, right). Above the SN, the red nucleus can be identified.
I R O N A N D P A R K I N S O N ' S D I S E A S E
A New Therapeutic Strategy of Conservative Chelation Based on Iron Scavenging and Redeployment
The implication of siderosis and iron toxicity has largely been based on the protective effects of iron chelation in cell and animal models. [1] [2] [3] [7] [8] [9] [10] [11] 34, 35 However, for any chelator to be of clinical value in disorders of regional siderosis, it ought to be endowed with the requisite accessibility to the relevant sites and differential specificity to spare unaffected areas of the organism from scavenging an essential element. 36 Different agents with iron-chelating features (eg, deferoxamine, clioquinol, VK28, M30, and natural plantderived polyphenol flavonoids) have been assessed but not progressed to clinical trial.
DFP is exceptional among iron chelators in its ability to cross membranes, including the blood-brain barrier, and to chelate components of the cellular labile iron pool in brain tissue. 36 DFP has the remarkable ability to rescue transfusional hemosiderosis in the hearts of b-thalassemia patients without inducing anemia, largely attributable to the redeployment of captured iron to extracellular iron-free Tf and subsequent distribution (Fig. 3, Table 1 ). 36 The conservative repositioning strategy has been applied to PD using DFP at the relatively low oral dose of 30 mg/kg/day. 9 An early-stage PD patient pilot study using a delayed-start paradigm (6 months DFP or placebo pretreatment followed by 12 months DFP for all) yielded a significant reduction in SNc siderosis, particularly in the group that started early with DFP. Compared with placebo, this remained stable until completion (month 18). A concomitant clinical benefit was noted at 6 months, with a 3-point improvement in the motor Unified Parkinson's disease rating scale (UPDRS) in the early-start group (21.6 6 8) versus the delayed-start group (24 6 6). Importantly, at 12 months these "early-start" patients retained a significantly lower motor handicap (1 point on the motor UPDRS, 21.3 6 8) compared with the delayed-start group (22.8 6 6), signifying a disease-modifying effect. 9 The conservative mode of chelation was reflected by an absence of systemic iron loss with patients showing normal iron indices that were unaltered after 18 or 24 months of DFP treatment (except a mild ferritin reduction in blood and cerebrospinal fluid). Positive clinical outcomes were recently confirmed by another randomized, double-blind, placebocontrolled trial. In this smaller-sized trial, DFP reduced dentate and caudate nucleus iron content and indicated a trend toward improvement in motor UPDRS scores and quality of life. 37 In both trials DFP had a good safety profile, despite the requirement of weekly blood counts during the first 6 months to monitor reversible neutropenia that may occur in 1%-3% of patients treated with DFP.
These promising results have now led to a large phase 2 European multicenter, parallel-group, placebo-controlled, randomized clinical trial, of which the aim is to evaluate whether DFP can slow progressive impairment in PD patients (www.fairpark2.eu). Three hundred and thirty-eight patients with de novo PD are planned for randomization to either DFP (30 mg/kg/day in 2 doses a day) or placebo for 9 months. All will then participate in a 1-month posttreatment monitoring period. To assess Alterations in the iron regulatory pathway and phospholipid oxidation are implicated in Parkinson's disease pathology. Increased intracellular iron occurs by enhanced import of iron within transferrin (Tf) through transferrin receptor (TfR) endocytosis, which is promoted by asynuclein (a-syn), and increased import of Fe 21 through the divalent metal transporter 1 (DMT1). In addition, iron export is impaired through the destabilization of ferroportin (Fpn) on the cell surface by b-amyloid precursor protein (APP) or ceruloplasmin (CP). When the storage protein neuromelanin (Nm) and ferritin (Ft) are no longer able to safely store intracellular iron, the labile pool of iron is elevated and catalyzes the formation of phospholipid hydroperoxides. Cystine uptake through the X c-antiporter (in oxidative conditions) or the alanine, serine, cysteine-preferring (ASC) system (in reducing conditions) is required for biosynthesis of glutathione (GSH). Glutathione peroxidase 4 (Gpx4) uses 2 GSH molecules to safely reduce phospholipid hydroperoxides to their corresponding lipid-alcohols, producing H 2 O and glutathione disulfide (GSSG) as byproducts. Elevated levels of intracellular iron with depletion of Gpx4, as evidenced in models of PD, promote the accumulation of phospholipid hydroperoxides, leading to disruption in membrane integrity through a ferroptotic pathway. Reducing the labile iron pool (ie, deferiprone) or depleting phospholipid hydroperoxides (ie, liproxstatin-1 or ferrostatin-1) are thus promising targets for inhibiting ferroptosis in PD pathology.
FIG. 3.
A conservative mode of chelation based on (a) the scavenging of iron that accumulated intracellularly (organelle, cell, or tissue), and (b) its redeployment to another cell or tissue compartment, either by the chelator or via iron transferred to circulating transferrin. The presence of apotransferrin in circulating fluids ensures that iron scavenged from cells is conserved and redeployed primarily to areas of iron deficiency.
the hypothesized disease-modifying effect of DFP, the primary efficacy criterion will be the total score on the UPDRS, encompassing motor and nonmotor symptoms as well as activities of daily living. Secondary criteria include cognition, quality of life, quantitative continuous motor activity in the home environment, and a health economics questionnaire. Potential surrogate and theranostic biomarkers of efficacy and safety will also be analyzed (ie, a wide range of iron, dopamine, and asynuclein markers). These include the imaging measurement of iron content (MRI R2*/QSM and transcranial ultrasound) and dopamine content (dopamine transporter SPECT imaging). Since the initiation of the FAIR-PARK-II trial, a further phase 2 trial at sites in both Europe and Canada has begun to analyze different DFP doses ranging from 10 to 40 mg/kg/day to evaluate clinical outcome over the same treatment period.
Conclusions and Future Directions
Cell iron dyshomeostasis has been implicated in a wide range of neurodegenerative disorders other than PD, such as Alzheimer's disease (AD; cortical iron elevation), 38 amyotrophic lateral sclerosis (ALS; elevated iron in motor neuron pathways), 39 and the less prevalent brain iron accumulation. This maldistribution of iron might represent a pathological form of regional siderosis that could be treated by a conservative mode of chelation based on drug-mediated iron redistribution, as currently under clinical evaluation in PD, pantothenate kinase-associated neurodegeneration type 2, ALS, and AD. The aim is to slow down disease progression, but complementary strategies may also block iron-dependent death pathways such as ferroptosis or stimulate cell repair pathways that promote glutathione formation or inhibit iron-dependent prolyl hydroxylases. 9, 33, 40 , It is hoped that with new biomarker developments in iron-sensitive MRI sequencing, clinical trials such as the one presented here for conservative iron chelation may change the future clinical practice of PD.
